

Amir Sonnenblick

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8116747/publications.pdf>

Version: 2024-02-01

55
papers

1,285
citations

471509

17
h-index

377865

34
g-index

56
all docs

56
docs citations

56
times ranked

2780
citing authors

#	ARTICLE	IF	CITATIONS
1	An update on PARP inhibitors“ moving to the adjuvant setting. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 27-41.	27.6	316
2	Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2“Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1421-1429.	1.6	116
3	Pregnancy After Breast Cancer in Patients With Germline <i>BRCA</i> Mutations. <i>Journal of Clinical Oncology</i> , 2020, 38, 3012-3023.	1.6	69
4	Clinical Proteomics of Breast Cancer Reveals a Novel Layer of Breast Cancer Classification. <i>Cancer Research</i> , 2018, 78, 6001-6010.	0.9	64
5	Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy. <i>Cancer Biology and Therapy</i> , 2011, 12, 165-168.	3.4	63
6	Interplay between MITF, PIAS3, and STAT3 in Mast Cells and Melanocytes. <i>Molecular and Cellular Biology</i> , 2004, 24, 10584-10592.	2.3	56
7	Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer. <i>BMC Medicine</i> , 2015, 13, 177.	5.5	45
8	Tissue microarray-based study of patients with lymph node-positive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3 (tyrosine705-STAT3) is a marker of good prognosis. <i>Clinical and Translational Oncology</i> , 2012, 14, 232-236.	2.4	41
9	Final 10-year results of the Breast International Group 2“98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. <i>European Journal of Cancer</i> , 2015, 51, 1481-1489.	2.8	32
10	Regulation of Cellular Heterogeneity and Rates of Symmetric and Asymmetric Divisions in Triple-Negative Breast Cancer. <i>Cell Reports</i> , 2018, 24, 3237-3250.	6.4	31
11	Tumor STAT3 tyrosine phosphorylation status, as a predictor of benefit from adjuvant chemotherapy for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 407-413.	2.5	30
12	Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up?. <i>Cancer Treatment Reviews</i> , 2014, 40, 1089-1095.	7.7	30
13	Interleukin 6“ dependent genomic instability heralds accelerated carcinogenesis following liver regeneration on a background of chronic hepatitis. <i>Hepatology</i> , 2017, 65, 1600-1611.	7.3	28
14	Decoding cancer heterogeneity: studying patient-specific signaling signatures towards personalized cancer therapy. <i>Theranostics</i> , 2019, 9, 5149-5165.	10.0	28
15	Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer. <i>International Journal of Cancer</i> , 2017, 140, 2145-2149.	5.1	27
16	Heparanase Accelerates Obesity-Associated Breast Cancer Progression. <i>Cancer Research</i> , 2019, 79, 5342-5354.	0.9	26
17	Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw037.	6.3	24
18	Liver Failure on the Background of Pseudocirrhosis in Patients with Liver Metastasis from Breast Cancer, Who Responded to Treatment. <i>Onkologie</i> , 2011, 34, 199-201.	0.8	18

#	ARTICLE	IF	CITATIONS
19	pAKT pathway activation is associated with PIK3CA mutations and good prognosis in luminal breast cancer in contrast to p-mTOR pathway activation. <i>Npj Breast Cancer</i> , 2019, 5, 7.	5.2	18
20	Heparanase augments insulin receptor signaling in breast carcinoma. <i>Oncotarget</i> , 2017, 8, 19403-19412.	1.8	18
21	Sorafenib treatment during partial hepatectomy reduces tumorigenesis in an inflammation-associated liver cancer model. <i>Oncotarget</i> , 2016, 7, 4860-4870.	1.8	17
22	The History of Early Breast Cancer Treatment. <i>Genes</i> , 2022, 13, 960.	2.4	16
23	New Strategies in Breast Cancer: The Significance of Molecular Subtypes in Systemic Adjuvant Treatment for Small T1a,bNOMO Tumors. <i>Clinical Cancer Research</i> , 2014, 20, 6242-6246.	7.0	15
24	Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial. <i>Oncotarget</i> , 2015, 6, 30306-30316.	1.8	14
25	Cost Effectiveness of Whole Population BRCA Genetic Screening for Cancer Prevention in Israel. <i>Cancer Prevention Research</i> , 2021, 14, 455-462.	1.5	14
26	Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer. <i>International Journal of Cancer</i> , 2020, 147, 266-276.	5.1	13
27	Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants. <i>Npj Breast Cancer</i> , 2021, 7, 16.	5.2	13
28	Multiple Roles of IL6 in Hepatic Injury, Steatosis, and Senescence Aggregate to Suppress Tumorigenesis. <i>Cancer Research</i> , 2021, 81, 4766-4777.	0.9	12
29	p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial. <i>International Journal of Oncology</i> , 2018, 52, 424-432.	3.3	9
30	Ev vivo organ culture as potential prioritization tool for breast cancer targeted therapy. <i>Cancer Biology and Therapy</i> , 2018, 19, 645-648.	3.4	9
31	<p>Comparison of Patient Susceptibility Genes Across Breast Cancer: Implications for Prognosis and Therapeutic Outcomes</p>. <i>Pharmacogenomics and Personalized Medicine</i> , 2020, Volume 13, 227-238.	0.7	8
32	Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 67.	5.2	8
33	Renal tubular acidosis secondary to capecitabine, oxaliplatin, and cetuximab treatment in a patient with metastatic colon carcinoma: a case report and review of the literature. <i>International Journal of Clinical Oncology</i> , 2010, 15, 420-422.	2.2	7
34	Long-term outcome of continuous 5-fluorouracil/cisplatin-based chemotherapy followed by chemoradiation in patients with resected gastric cancer. <i>Medical Oncology</i> , 2012, 29, 3035-3038.	2.5	6
35	Gemcitabine in combination with paclitaxel for advanced soft-tissue sarcomas. <i>Molecular and Clinical Oncology</i> , 2015, 3, 829-832.	1.0	6
36	STAT3 activation in HER2 -positive breast cancers: Analysis of data from a large prospective trial. <i>International Journal of Cancer</i> , 2021, 148, 1529-1535.	5.1	6

#	ARTICLE	IF	CITATIONS
37	Clinical Implications of Sub-grouping HER2 Positive Tumors by Amplicon Structure and Co-amplified Genes. Scientific Reports, 2019, 9, 18795.	3.3	5
38	Patient (pt)-reported function and symptoms in APHINITY: A randomized comparison of chemotherapy (C) + trastuzumab (H) + placebo (Pla) versus C + H + pertuzumab (P) as adjuvant therapy in pts with HER2-positive early breast cancer (EBC).. Journal of Clinical Oncology, 2018, 36, 521-521.	1.6	5
39	Defects in homologous recombination repair genes are associated with good prognosis and clinical sensitivity to DNA-damaging agents in pancreatic cancer: A case report. Molecular and Clinical Oncology, 2018, 8, 683-685.	1.0	4
40	SYK expression level distinguishes control from BRCA1-mutated lymphocytes. Cancer Management and Research, 2018, Volume 10, 589-598.	1.9	4
41	Reversal of acquired resistance to pazopanib in soft tissue sarcoma with addition of an mTOR inhibitor: A case report.. Journal of Clinical Oncology, 2013, 31, e21508-e21508.	1.6	3
42	Accelerated carcinogenesis following liver resection in chronically inflamed livers: A window of opportunity for treatment. Biomedical Reports, 2017, 6, 545-548.	2.0	2
43	Diagnostic workup of early-stage breast cancer: can we choose more wisely?. Breast Cancer Research and Treatment, 2020, 183, 741-748.	2.5	2
44	Ethnicity, recurrence score distribution, and clinical outcomes in ER ⁺ HER2 ⁻ negative breast cancer patients in Israel: A registry analysis. Breast Journal, 2020, 26, 2096-2098.	1.0	2
45	KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2- locally recurrent inoperable or metastatic breast cancer.. Journal of Clinical Oncology, 2022, 40, TPS1118-TPS1118.	1.6	2
46	The effect of non-oncology drugs on clinical and genomic risk in early luminal breast cancer.. Journal of Clinical Oncology, 2021, 39, e12505-e12505.	1.6	1
47	Abstract PD10-04: Phase Ib/II open-label, randomized trial of atezolizumab (atezo) with ipatasertib (ipat) and fulvestrant (fulv) vs control in MORPHEUS-HR+ breast cancer (M-HR+ BC) and atezo with ipat vs control in MORPHEUS triple negative breast cancer (M-TNBC). Cancer Research, 2022, 82, PD10-04-PD10-04.	0.9	1
48	Potential Refinement of Recurrence Score by pSTAT3 Status. Genes, 2022, 13, 438.	2.4	1
49	Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial. Anticancer Research, 2019, 39, 797-802.	1.1	0
50	The impact of tumor detection method on genomic and clinical risk and chemotherapy recommendation in early hormone receptor positive breast cancer. Breast, 2021, 60, 78-85.	2.2	0
51	Characteristics of sarcoma patients with long-term response to gemcitabine and paclitaxel.. Journal of Clinical Oncology, 2012, 30, 10034-10034.	1.6	0
52	Abstract PD5-06: Safety of assisted reproductive technologies (ART) following treatment completion in young women with germline BRCA pathogenic variants having a pregnancy after breast cancer. Cancer Research, 2022, 82, PD5-06-PD5-06.	0.9	0
53	Abstract P1-08-14: Differences in Recurrence Score (RS) results between primary and second primary breast cancer (BC): Exploratory analysis of the Clalit Health Services (CHS) registry. Cancer Research, 2022, 82, P1-08-14-P1-08-14.	0.9	0
54	Abstract P5-13-19: Sarcopenia and skeletal muscle density as predictors of toxicity in patients with metastatic breast cancer receiving alpelisib. Cancer Research, 2022, 82, P5-13-19-P5-13-19.	0.9	0

#	ARTICLE	IF	CITATIONS
55	Recurrence Score (RS) results, clinicopathologic characteristics, treatments, and outcomes in primary versus subsequent breast cancer (BC): Exploratory analysis of the Clalit Health Services (CHS) registry.. <i>Journal of Clinical Oncology</i> , 2022, 40, 565-565.	1.6	0